sCD163 in HELLP Syndrome
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexFemale
Age18-45
SponsorAssiut University
About this trial
Primary Aim:
\_To investigate the diagnostic potential of soluble CD163 (sCD163)as a novel biomarker for the early detection of HELLP syndrome, assessing its sensitivity and specificity compared to current diagnostic markers.
Secondary Aims:
1. To evaluate the correlation between sCD163 levels and the clinical severity of HELLP syndrome, including complications such as liver dysfunction, thrombocytopenia, and hemolysis. 2. To compare sCD163 levels across different stages of HELLP syndrome (partial vs. complete and other hypertensive disorders of pregnancy (e.g., preeclampsia).
Eligibility criteria
Qualifiers
Hemolysis (LDH >600 U/L + abnormal smear or bilirubin ≥1.2 mg/dL)
AST/ALT ≥70 U/L
Platelets <100,000/μL
Gestational age (20-42) weeks
Disqualifiers
Autoimmune diseases (e.g., lupus, rheumatoid arthritis)
Chronic kidney/liver disease
Active infections (e.g., HIV, hepatitis)
Fetal anomalies or intrauterine fetal demise at diagnosis.
Trial design
Treatments tested in this trial
- sCD163 level
Treatment groups
70 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Source ClinicalTrials.gov